Adil Daud, MD
Enriched profileClinical Professor, Medical Oncology (Melanoma and Skin Cancer); co-director of the Melanoma Center · University of California, San Francisco
Adil Daud is Clinical Professor, Medical Oncology (Melanoma and Skin Cancer); co-director of the Melanoma Center at University of California, San Francisco. OpenAlex indexes 596 publications with 48,936 citations (h-index 89); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 21 Oct 2026
Overview
Updated 21 Oct 2026
Adil Daud, MD, is Clinical Professor, Medical Oncology (Melanoma and Skin Cancer) at University of California, San Francisco. The public record shows 596 publications with 48,936 citations (h-index 89), centered on Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 16 companies.
- Most recent indexed publication: 2026 · Pigment cell & melanoma research
- Top research focus: Cancer Immunotherapy and Biomarkers
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 21 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 252.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 21 Oct 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
Sponsor: University of California, San Diego
- XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
Sponsor: University of California, San Francisco
Industry payments
Updated 21 Oct 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202513 payments$16,765openpaymentsdata.cms.gov ↗
- Regeneron Pharmaceuticals, Inc.Program year202511 payments$12,281openpaymentsdata.cms.gov ↗
- Celltrion, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
53.3%Corticosteroid26.7%Prednisone100%Part D<11 patientsSerotonin-3 Receptor Antagonist26.7%Ondansetron Odt100%Part D<11 patientsHormonal (systemic)
46.7%l-Thyroxine46.7%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 21 Oct 2026
137 congress contributions (2004–2026) across AACR, ASCO, ESMO per OpenAlex. The most recent:
- A phase 1/2 dose-escalation/expansion study of REGN10597 (anti–PD-1–IL2Rα-IL2) in patients with advanced solid tumors.
ASCO Annual Meeting
ASCO2026Co-author - Phase 1/2 dose escalation/expansion study of REGN10597 (anti–PD-1–IL2Rα-IL2) in patients with advanced solid tumors.
ASCO Annual Meeting
ASCO2026Co-author - Abstract 7125: Distinct CD8+T cell subsets in advanced melanoma patients with liver metastasis
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 21 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines.
Pigment cell & melanoma research
Article2026 - PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.
Nature communications
Article2026
Most-cited works
by citation count (OpenAlex)- 01Pembrolizumab versus Ipilimumab in Advanced MelanomaArticle5,879 citations2015
- 02Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaArticle3,395 citations2013
- 03Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsArticle2,810 citations2012
- 04
- 05
Network
Updated 21 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 21 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
melanomasurgery.ucsf.edu/node/12401
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →melanomasurgery.ucsf.edu ↗ - Other
ucsfhealthhemonc.ucsf.edu/people/adil-daud
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ucsfhealthhemonc.ucsf.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 21 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- Medical degree
Government Medical College, Nagpur
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
Editorial & leadership roles
journal and society appointments- Consortium Chair
UCSF Melanoma Skin Cancer Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →melanoma.ucsf.edu ↗
Awards & honors
honors on the public record- Young Investigator Award
American Society of Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
Secondary affiliations
appointments beyond the home institution- Former researcher
Moffitt Cancer Center, Tampa, Florida (seven years, before joining UCSF)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologytoday.researchtopractice.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Emmanuelle Waubant, MD
University of California, San Francisco
Peter Ganz, MD
University of California, San Francisco
Joel Palefsky, MD
University of California, San Francisco
Peter Hunt, MD
University of California, San Francisco
Jedd Wolchok, MD
Weill Cornell Medicine
Frank Hodi, MD
Dana-Farber Cancer Institute
Mario Sznol, MD
University of Miami Miller School of Medicine
Igor Puzanov, MD
Roswell Park Comprehensive Cancer Center